What is the Onesource Specialty Pharma Ltd share price today?

The share price of NSE:ONESOURCE-EQ on 07 Sep 2026 (as of 10:59:56 IST) is ₹1558.70.

What is the NSE:ONESOURCE-EQ 52 week high low price?

Over the past 52 weeks (as of 07 Sep 2026), the NSE:ONESOURCE-EQ 52 week high low range shows a high of ₹1925.00 and a low of ₹1057.00.

What is the Onesource Specialty Pharma Ltd market cap?

As on 07 Sep 2026, Onesource Specialty Pharma Ltd market cap is ₹17587.40 Cr.

What is the shareholding pattern of Onesource Specialty Pharma Ltd Stock?

The shareholding pattern of Onesource Specialty Pharma Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 30.48% Foreign Institutional Investors (FII): 19.19% Domestic Institutional Investors (DII): 10.39% Mutual Funds: 12.98% Retail & Others: 26.96% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Onesource Specialty Pharma Ltd?

The Price-to-Earnings (PE) ratio of Onesource Specialty Pharma Ltd is 0, and the Price-to-Book (PB) ratio is 2.90, as on 07 Sep 2026.

Onesource Specialty Pharma Share Price

1594.60-2.10 (-0.13%)

-10.51% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-0.13%

1 Week

-0.02%

1 Month

+5.18%

3 Month

+2.48%

6 Month

+10.19%

YTD

-11.93%

1 Year

-10.51%

5 Year

10 Year

Max

-11.41%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

1579.20

1478.00

1316.40

1057.00

High

1605.00

1643.00

1657.50

1755.20

1917.80

1925.00

About

OneSource Specialty Pharma is evolved into an integrated, multimodal specialty pharmaceutical CDMO. The company specialises in offering end-to-end solutions across biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatin Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

CIPLANSE

LAURUSLABSNSE

MANKINDNSE

DRREDDYNSE

AUROPHARMANSE

LUPINNSE

ONESOURCENSE

LTP

1W Low

1W High

Market cap (₹)

1849.9+12.6 (0.69%)

1832.20

1891.50

4,47,476Cr

9602+227 (2.42%)

9312.50

9740

2,54,764Cr

4928.5+88.5 (1.83%)

4848.50

5010

1,89,423Cr

1180.3+20.3 (1.75%)

1152.10

1190.60

1,16,658Cr

1399+4.5 (0.32%)

1364.50

1419

1,11,484Cr

2026.2+72.2 (3.69%)

1963.80

2055.30

1,09,943Cr

2500+199.3 (8.66%)

2303

2504.30

1,01,712Cr

1200.4+15.4 (1.30%)

1185

1222

1,01,005Cr

1716-18 (-1.04%)

1689.30

1740

99,253Cr

2100.7+17.7 (0.85%)

2080

2135

96,031Cr

1594.6-0.3 (-0.02%)

1579.20

1643

18,321Cr

Onesource Specialty Pharma Share Price

1594.60-2.10 (-0.13%)

-10.51% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years-

3 years232%

Last year-2%

Compounded Profit Growth

10 years-

5 years-

3 years-

Last year-327%

Stock Price CAGR

10 years-

5 years-

3 years-

1 year-9%

Return on Equity

10 years-24%

5 years-24%

3 years-21%

Last year-1%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	-	232%	-2%
-	-	-	-327%
-	-	-	-9%
-24%	-24%	-21%	-1%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

CIPLA

LAURUSLABS

MANKIND

DRREDDY

AUROPHARMA

LUPIN

ONESOURCE

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,849.9	₹447476 Cr	37	12.07	62.82	₹11479 Cr
9,602	₹254764 Cr	87.1	34.04	128.41	₹2568 Cr
4,928.5	₹189423 Cr	86.85	16.72	97.06	₹2163 Cr
1,180.3	₹116658 Cr	25.85	9.42	62.53	₹5040 Cr
1,399	₹111484 Cr	33.08	9.77	57.87	₹3879 Cr
2,026.2	₹109943 Cr	100.55	6.8	29.25	₹889 Cr
2,500	₹101712 Cr	49.79	13.75	71.08	₹1913 Cr
1,200.4	₹101005 Cr	31.35	5.32	63.99	₹4196 Cr
1,716	₹99253 Cr	26.73	17.95	96.84	₹3505 Cr
2,100.7	₹96031 Cr	17.37	30.95	154.35	₹5333 Cr
1,594.6	₹18321 Cr	—	2.18	20.44	-₹74 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Secured Loans

Unsecured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
—	—	—	—	—
₹11 Cr	₹11 Cr	₹4 Cr	₹4 Cr	₹3 Cr
₹7 Cr	₹12 Cr	₹8 Cr	₹6 Cr	₹0
₹5813 Cr	₹5857 Cr	₹384 Cr	₹775 Cr	₹1009 Cr
₹5813 Cr	₹5857 Cr	₹384 Cr	₹775 Cr	₹1009 Cr
₹5831 Cr	₹5881 Cr	₹396 Cr	₹785 Cr	₹1012 Cr
₹564 Cr	₹181 Cr	₹12 Cr	₹285 Cr	₹597 Cr
₹0	₹38 Cr	₹259 Cr	₹50 Cr	₹0
₹135 Cr	₹155 Cr	₹0	₹0	₹0
₹220 Cr	₹166 Cr	₹8 Cr	₹21 Cr	₹22 Cr
₹18 Cr	₹16 Cr	₹2 Cr	₹2 Cr	₹2 Cr
₹937 Cr	₹556 Cr	₹282 Cr	₹358 Cr	₹621 Cr
—	—	—	—	—
₹375 Cr	₹176 Cr	₹81 Cr	₹95 Cr	₹63 Cr
₹476 Cr	₹478 Cr	₹536 Cr	₹573 Cr	₹559 Cr
₹576 Cr	₹436 Cr	₹10 Cr	₹194 Cr	₹184 Cr
₹27 Cr	₹24 Cr	₹4 Cr	₹4 Cr	₹3 Cr
₹1454 Cr	₹1114 Cr	₹631 Cr	₹865 Cr	₹809 Cr
₹8222 Cr	₹7550 Cr	₹1309 Cr	₹2009 Cr	₹2442 Cr
₹1287 Cr	₹1165 Cr	₹1137 Cr	₹1144 Cr	₹150 Cr
₹1276 Cr	₹772 Cr	₹562 Cr	₹837 Cr	₹1154 Cr
—	—	—	—	—
₹6844 Cr	₹6666 Cr	₹1139 Cr	₹1633 Cr	₹1392 Cr
₹826 Cr	₹549 Cr	₹277 Cr	₹271 Cr	₹160 Cr
₹6017 Cr	₹6118 Cr	₹863 Cr	₹1361 Cr	₹1231 Cr
₹314 Cr	₹60 Cr	₹43 Cr	₹191 Cr	₹68 Cr
₹10 Cr	₹7 Cr	₹4 Cr	₹0	₹0
₹10 Cr	₹7 Cr	₹4 Cr	₹0	₹0
₹227 Cr	₹121 Cr	₹77 Cr	₹82 Cr	₹210 Cr
₹17 L	₹41 L	₹80 L	₹2 Cr	₹0
₹6784 Cr	₹6464 Cr	₹1132 Cr	₹1780 Cr	₹1931 Cr
—	—	—	—	—
₹5 Cr	₹9 Cr	₹16 Cr	₹5 Cr	₹0
₹439 Cr	₹158 Cr	₹11 Cr	₹133 Cr	₹275 Cr
₹690 Cr	₹417 Cr	₹55 Cr	₹4 Cr	₹24 Cr
₹98 Cr	₹301 Cr	₹60 Cr	₹80 Cr	₹170 Cr
₹29 Cr	₹40 Cr	₹8 Cr	₹1 Cr	₹31 Cr
₹177 Cr	₹162 Cr	₹26 Cr	₹6 Cr	₹11 Cr
₹1438 Cr	₹1086 Cr	₹176 Cr	₹228 Cr	₹511 Cr
-₹16 Cr	-₹27 Cr	-₹454 Cr	-₹637 Cr	-₹298 Cr
₹8222 Cr	₹7550 Cr	₹1309 Cr	₹2009 Cr	₹2442 Cr
₹508	₹513	₹97	₹194	₹333
₹508	₹513	₹97	₹194	₹333

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
-₹92 Cr	-₹68 Cr	-₹391 Cr	-₹800 Cr	-₹231 Cr
₹386 Cr	₹427 Cr	₹288 Cr	₹604 Cr	₹147 Cr
-₹277 Cr	-₹420 Cr	-₹4 Cr	₹22 Cr	-₹332 Cr
₹17 Cr	-₹61 Cr	-₹107 Cr	-₹174 Cr	-₹416 Cr
₹9 Cr	-₹68 Cr	-₹107 Cr	-₹163 Cr	-₹416 Cr
-₹495 Cr	-₹201 Cr	₹511 Cr	-₹68 Cr	-₹692 Cr
₹359 Cr	₹412 Cr	-₹391 Cr	₹118 Cr	₹1162 Cr
-₹127 Cr	₹143 Cr	₹13 Cr	-₹112 Cr	₹54 Cr
₹165 Cr	₹22 Cr	₹9 Cr	₹122 Cr	₹67 Cr
₹0	₹2 L	₹0	₹0	₹0
₹38 Cr	₹165 Cr	₹22 Cr	₹9 Cr	₹122 Cr

Fundamental Ratios

Consolidated

Standalone

Onesource Specialty Pharma Share Price

1594.60-2.10 (-0.13%)

-10.51% past 1 Year

Shareholding summary

Promoters

30.48%

FII

19.19%

DII

10.39%

12.98%

Others

26.96%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
30.48%	30.48%	29.93%	29.77%	29.79%	34.25%
19.19%	17.50%	19.24%	19.39%	18.69%	18.54%
10.39%	10.48%	9.65%	9.36%	8.90%	9.58%
12.98%	10.13%	9.02%	8.99%	9.06%	8.32%
26.96%	31.41%	32.16%	32.49%	33.56%	29.31%

Bulk & block deals

Name

Fidelity Securities Fund: Fidelity Blue Chip Growth Fund

Authum Investment & Infrastructure Limited

Nova Global Opportunities Fund Pcc - Touchstone

Authum Investment & Infrastructure Limited

Karuna Business Solutions Llp

Amansa Holding Private Ltd.

Medella Holdings Pte. Ltd.

Cpt Research & Mgmt Co T/A Cpt World Investors

Motilal Oswal Mutual Fund A/C Motilal Oswal Large And Midcap Fund

Medella Holdings Pte. Ltd.

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
21 Apr 2026	Purchase	308.70 Cr	₹1,530	20.18 L	Bulk	1.759493	NSE
21 Apr 2026	Purchase	26.88 Cr	₹1,556.69	1.73 L	Bulk	0.150574	NSE
21 Apr 2026	Sell	161.86 Cr	₹1,530	10.58 L	Bulk	0.922539	NSE
21 Apr 2026	Sell	145.36 Cr	₹1,530.09	9.50 L	Bulk	0.828443	NSE
17 Nov 2025	Purchase	34.70 Cr	₹1,735	2 L	Block	0.174409	NSE
17 Nov 2025	Sell	34.70 Cr	₹1,735	2 L	Block	0.174409	NSE
15 May 2025	Sell	138.65 Cr	₹1,568.04	8.84 L	Bulk	0.771071	BSE
31 Jan 2025	Purchase	176.16 Cr	₹1,545	11.40 L	Bulk	0.994279	NSE
31 Jan 2025	Purchase	163.04 Cr	₹1,545	10.55 L	Bulk	0.920225	NSE
31 Jan 2025	Sell	301.53 Cr	₹1,552.90	19.42 L	Bulk	1.693293	NSE

Insider trading & SAST

Client name

Pronomz Ventures Llp & Pacs

Tenshi Pharmaceuticals Pvt Ltd & Pacs

Tenshi Pharmaceuticals Pvt Ltd

Tenshi Pharmaceuticals Pvt Ltd & Pacs

Pronomz Ventures Llp & Pacs

Tenshi Pharmaceuticals Pvt Ltd & Pacs

Pronomz Ventures Llp

Tenshi Pharmaceuticals Private Limited

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
17 Feb 2026	Promoter	Acquisition	0.04	30.23	0	—	45 K	02 Feb 2026	Market	3,46,50,105	SAST	29(2)	—
17 Feb 2026	Promoter	Acquisition	0.07	30.48	0	—	85 K	04 Feb 2026	Market	3,49,40,105	SAST	29(2)	—
17 Feb 2026	Promoter	Acquisition	0.18	30.41	0	—	2.05 L	02 Feb 2026	Market	3,48,55,105	SAST	29(2)	—
16 Feb 2026	Promoter	Acquisition	0.07	30.17	0	—	75 K	30 Jan 2026	Market	3,45,71,199	SAST	29(2)	—
16 Feb 2026	Promoter	Acquisition	0.03	30.19	0	—	33.91 K	30 Jan 2026	Market	3,46,05,105	SAST	29(2)	—
10 Feb 2026	Promoter	Acquisition	0.17	30.1	0	—	2 L	28 Jan 2026	Market	3,44,96,199	SAST	29(2)	—
06 Feb 2026	Promoter Group	Acquisition	0.03926	2.41	5.10 Cr	₹1,132.23	45 K	02 Feb 2026	Market Purchase	27,61,308	Insider Trading	—	Equity Shares
06 Feb 2026	Promoter Group	Acquisition	0.029581	2.37	4.05 Cr	₹1,194.02	33.91 K	30 Jan 2026	Market Purchase	27,16,308	Insider Trading	—	Equity Shares
06 Feb 2026	Promoter	Acquisition	0.065433	18.15	8.71 Cr	₹1,161.78	75 K	30 Jan 2026	Market Purchase	2,07,99,714	Insider Trading	—	Equity Shares
06 Feb 2026	Promoter	Acquisition	0.17885	18.33	23.88 Cr	₹1,164.76	2.05 L	02 Feb 2026	Market Purchase	2,10,04,714	Insider Trading	—	Equity Shares

Onesource Specialty Pharma Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Onesource Specialty Pharma Share Price

Onesource Specialty Pharma Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Onesource Specialty Pharma Share Price

Onesource Specialty Pharma Share Price

Oscillators

Moving averages

Onesource Specialty Pharma Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Onesource Specialty Pharma Share Price

Corporate Actions

Company details

Onesource Specialty Pharma Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Onesource Specialty Pharma Share Price

News

Onesource Specialty Pharma posts higher Q1 EBITDA and stable margin

Onesource Specialty Pharma reports higher Q1 revenue at Rs 446 crores

Onesource Specialty Pharma Q1 net profit more than doubles year-on-year

Onesource Specialty Pharma, Formycon AG sign biosimilars manufacturing partnership

Onesource Specialty Pharma says Dr Reddys supply delay non-disruptive, expansion on track

Onesource Specialty Pharma sterile unit clears USFDA audit with minor note

Onesource Specialty Pharma informs about updates

Onesource Specialty - Quaterly Results

Onesource Specialty Pharma informs about outcome of board meeting

Onesource Specialty reports Profit after tax of 21.48 Crores, in the March 2026 quarter

Onesource Specialty Pharma Q4 Results: EBITDA Declines 69% YoY

Onesource Specialty Pharma Q4 FY2026 Revenue Decline YoY

Onesource Specialty Pharma Q4 Net Profit Declines 87.8% YoY to Rs 21.40 Crores

OneSource Specialty Pharma informs about press release

OneSource Specialty’s partner gets Health Canada nod for generic version of Ozempic

Onesource Specialty Pharma Backs Canada's Approval of Second Generic Semaglutide.

Onesource Specialty Identifies Semaglutide as Key Opportunity and Canada as Significant Market.

OneSource Specialty Pharma informs about press release

OneSource Specialty Pharma shines on securing EU GMP certificate for SPD facility

Onesource Specialty’s partner gets Health Canada nod for Generic Semaglutide Injection

Onesource Specialty Pharma Ltd Share Price Today

Onesource Specialty Pharma Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator